RevieweNeurologicalSci2025
Meta meta-analysis of cardiovascular risk factors in Alzheimer's disease.
Review in eNeurologicalSci, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alzheimer's disease (AD) is the most common cause of dementia in the elderly. Identifying some of the cardiovascular risk factors for AD could be crucial for primary prevention and help reduce the incidence of AD. Objective: We aimed to perform a meta-meta-analysis of 3 studies to assess the effect of cholesterol, blood pressure and stroke on diagnosis of AD. Methods: The search was restricted to meta-analyses in the last three years assessing cholesterol, blood pressure, stroke and Alzheimer's disease. We applied the PRISMA guidelines. Results: The total effect of cholesterol on risk of AD was significant and heterogeneous. Subgroup analysis shows that LDL-C levels influence the development of AD. High SBP is associated with AD. The exploration of parameters (sex, age, study design, region, and BP measurements) shows that only region significantly moderates the relationship between BP and AD. Results report significant association between ischemic stroke (IS), hemorrhagic stroke (HS) and microinfarcts (MI) with the risk of AD. Conclusions: These results strengthen the evidence that the risk factors related to cardiovascular diseases increase risk for AD. Moreover, moderator analysis supports the robustness of our results. Therefore, future studies should use other uncontrolled factors, such as diabetes, to explain the relationship between these variables.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.